GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals
Edgar T. Overton,Somnuek Sungkanuparph,Michael K. Klebert,Michael Royal,Debra Demarco-Shaw,William G. Powderly,Judith A. Aberg +6 more
TLDR
In this article, the authors randomized 60 HIV-infected subjects to receive a booster dose of HBV vaccine with 250mcg GM-CSF as an adjuvant or booster vaccine alone.Abstract:
Background: Hepatitis B (HBV) vaccination is an important preventive intervention for HIV-infected population. Data regarding booster HBV vaccine for persons with low HBV surface antibody (sAb) titers after vaccination in this immunocompromised population is lacking. Methods: We randomized 60 HIV-infected subjects lacking HBV protection after completion of 3 doses of HBV vaccine to receive a booster dose of HBV vaccine with 250mcg GM-CSF as an adjuvant or booster vaccine alone. Results: GM-CSF was safe with expected side effects. However, only 35% of persons receiving GM-CSF developed protective sAb while 50% in vaccine only arm developed protection (P = 0.47). Overall, only 28% of subjects maintained protective sAb 1 year after vaccination. Conclusions: GM-CSF failed to improve responses to the booster HBV vaccination. Overall, response was poor with only 42% of persons responding at one month post-vaccination confirming booster vaccination with the current HBV vaccine has poor immunogenicity among HIV-infected persons. Further research is needed to develop optimal vaccination strategies in HIV-infected persons.read more
Citations
More filters
Journal ArticleDOI
Immunotherapeutic interventions in chronic hepatitis B virus infection: a review.
TL;DR: This paper will review immunotherapeutic interventions in the treatment of CHB and evaluate the effectiveness of IFN-α and Pegylated-IFN- α as adjuvants to inhibit HBV replication.
Journal ArticleDOI
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection
TL;DR: The evidence from this study is insufficient to support any recommendations regarding the use of hepatitis B vaccine in people living with HIV (PLHIV), and neither does this evidence demonstrate that hepatitis B Vaccine is unsafe in PLHIV.
Journal ArticleDOI
Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial
Romanee Chaiwarith,Jutarat Praparattanapan,Wilai Kotarathititum,Jiraprapa Wipasa,Kanokporn Chaiklang,Khuanchai Supparatpinyo +5 more
TL;DR: Despite the highly effectiveness of the standard hepatitis B vaccination regimen at 6 months after completion, the long-term immunogenicity was lower than the four double doses regimen among HIV-infected adults with CD4+ cell counts > 200 cells/mm3 and undetectable plasma HIV-1 RNA.
References
More filters
Journal ArticleDOI
Hepatitis B virus infection [1] (multiple letters)
Journal ArticleDOI
Hepatitis B virus infection.
TL;DR: This review addresses many aspects of HBV infection, including the role of the immune system in determining the outcome of clinical infection, recent developments in molecular studies of the virus, and new treatments capable of eradicating chronic infection.
DatasetDOI
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
TL;DR: The most recent version of the guidelines for the prevention and treatment of opportunistic infections (OI) in HIV-infected adults and adolescents was published in 2002 and 2004, respectively as mentioned in this paper.
Journal Article
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.
Eric E. Mast,Cindy M. Weinbaum,Anthony E. Fiore,Miriam J. Alter,Beth P. Bell,Lyn Finelli,Lance Rodewald,John M. Douglas,Robert S. Janssen,John W. Ward +9 more
TL;DR: This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection.
Journal ArticleDOI
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Chloe L. Thio,Eric C. Seaberg,Richard L. Skolasky,John P. Phair,Barbara R. Visscher,Alvaro Muñoz,David L. Thomas +6 more
TL;DR: Individuals coinfected with HIV-1 and HBV, especially those with low CD4+ nadir counts, are at increased risk for liver-related mortality, underscoring the importance of prevention, identification, and comprehensive management of hepatitis B in people infected withAIDS.